Intravenous antiplatelet therapy in patients with ST-segment elevation myocardial infarction undergoing primary percutaneous coronary intervention : A report from the INVEST-STEMI group.
Bleedings
Cangrelor
Outcomes
TIMI
Tirofiban
Journal
Journal of thrombosis and thrombolysis
ISSN: 1573-742X
Titre abrégé: J Thromb Thrombolysis
Pays: Netherlands
ID NLM: 9502018
Informations de publication
Date de publication:
13 Apr 2024
13 Apr 2024
Historique:
accepted:
14
03
2024
medline:
14
4
2024
pubmed:
14
4
2024
entrez:
13
4
2024
Statut:
aheadofprint
Résumé
The use of intravenous antiplatelet therapy during primary percutaneous coronary intervention (PPCI) is not fully standardized. The aim is to evaluate the effectiveness and safety of periprocedural intravenous administration of cangrelor or tirofiban in a contemporary ST-segment elevation myocardial infarction (STEMI) population undergoing PPCI. This was a multicenter prospective cohort study including consecutive STEMI patients who received cangrelor or tirofiban during PPCI at seven Italian centers. The primary effectiveness measure was the angiographic evidence of thrombolysis in myocardial infarction (TIMI) flow < 3 after PPCI. The primary safety outcome was the in-hospital occurrence of BARC (Bleeding Academic Research Consortium) 2-5 bleedings. The study included 627 patients (median age 63 years, 79% males): 312 received cangrelor, 315 tirofiban. The percentage of history of bleeding, pulmonary edema and cardiogenic shock at admission was comparable between groups. Patients receiving cangrelor had lower ischemia time compared to tirofiban. TIMI flow before PPCI and TIMI thrombus grade were comparable between groups. At propensity score-weighted regression analysis, the risk of TIMI flow < 3 was significantly lower in patients treated with cangrelor compared to tirofiban (adjusted OR: 0.40; 95% CI: 0.30-0.53). The risk of BARC 2-5 bleeding was comparable between groups (adjusted OR:1.35; 95% CI: 0.92-1.98). These results were consistent across multiple prespecified subgroups, including subjects stratified for different total ischemia time, with no statistical interaction. In this real-world multicenter STEMI population, the use of cangrelor was associated with improved myocardial perfusion assessed by coronary angiography after PPCI without increasing clinically-relevant bleedings compared to tirofiban.
Identifiants
pubmed: 38615155
doi: 10.1007/s11239-024-02970-7
pii: 10.1007/s11239-024-02970-7
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Informations de copyright
© 2024. The Author(s), under exclusive licence to Springer Science+Business Media, LLC, part of Springer Nature.
Références
Franchi F, Rollini F, Angiolillo DJ (2017) Antithrombotic therapy for patients with STEMI undergoing primary PCI. Nat Rev Cardiol 14(6):361–379. https://doi.org/10.1038/nrcardio.2017.18
doi: 10.1038/nrcardio.2017.18
pubmed: 28230176
(1997) EUROASPIRE. A European Society of Cardiology survey of secondary prevention of coronary heart disease: principal results. EUROASPIRE Study Group. European Action on Secondary Prevention through Intervention to Reduce Events. Eur Heart J 18(10):1569–82. https://doi.org/10.1093/oxfordjournals.eurheartj.a015136
Capodanno D, Alfonso F, Levine GN, Valgimigli M, Angiolillo DJ (2018) ACC/AHA versus ESC guidelines on dual antiplatelet therapy: JACC guideline comparison. J Am Coll Cardiol 72(23 Pt A):2915–31. https://doi.org/10.1016/j.jacc.2018.09.057
Scudiero F, Canonico ME, Sanna GD et al (2023) Dual antiplatelet therapy with 3(rd) generation P2Y(12) inhibitors in STEMI patients: impact of body mass index on loading dose-response. Cardiovasc Drugs Ther 37(4):695–703. https://doi.org/10.1007/s10557-022-07322-2
doi: 10.1007/s10557-022-07322-2
pubmed: 35175499
Parodi G, Valenti R, Bellandi B et al (2013) Comparison of prasugrel and ticagrelor loading doses in ST-segment elevation myocardial infarction patients: RAPID (Rapid Activity of Platelet Inhibitor Drugs) primary PCI study. J Am Coll Cardiol 61(15):1601–1606. https://doi.org/10.1016/j.jacc.2013.01.024
doi: 10.1016/j.jacc.2013.01.024
pubmed: 23500251
De Luca L, Steg PG, Bhatt DL, Capodanno D, Angiolillo DJ (2021) Cangrelor: clinical data, contemporary use, and future perspectives. J Am Heart Assoc 10(13):e022125. https://doi.org/10.1161/jaha.121.022125
doi: 10.1161/jaha.121.022125
pubmed: 34212768
pmcid: 8403274
Bhatt DL, Stone GW, Mahaffey KW et al (2013) Effect of platelet inhibition with cangrelor during PCI on ischemic events. N Engl J Med 368(14):1303–1313. https://doi.org/10.1056/NEJMoa1300815
doi: 10.1056/NEJMoa1300815
pubmed: 23473369
Stone GW, Bertrand ME, Moses JW et al (2007) Routine upstream initiation vs deferred selective use of glycoprotein IIb/IIIa inhibitors in acute coronary syndromes: the ACUITY timing trial. JAMA 297(6):591–602. https://doi.org/10.1001/jama.297.6.591
doi: 10.1001/jama.297.6.591
pubmed: 17299194
Giugliano RP, White JA, Bode C et al (2009) Early versus delayed, provisional eptifibatide in acute coronary syndromes. N Engl J Med 360(21):2176–2190. https://doi.org/10.1056/NEJMoa0901316
doi: 10.1056/NEJMoa0901316
pubmed: 19332455
Valgimigli M, Bueno H, Byrne RA et al (2018) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS: the task force for dual antiplatelet therapy in coronary artery disease of the European Society of Cardiology (ESC) and of the European Association for Cardio-Thoracic Surgery (EACTS). Eur Heart J 39(3):213–260. https://doi.org/10.1093/eurheartj/ehx419
doi: 10.1093/eurheartj/ehx419
pubmed: 28886622
Byrne RA, Rossello X, Coughlan JJ et al (2023) 2023 ESC Guidelines for the management of acute coronary syndromes. Eur Heart J Acute Cardiovasc Care. https://doi.org/10.1093/ehjacc/zuad107
Ibanez B, James S, Agewall S et al (2018) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: the task force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39(2):119–177. https://doi.org/10.1093/eurheartj/ehx393
doi: 10.1093/eurheartj/ehx393
pubmed: 28886621
Farooq V, van Klaveren D, Steyerberg EW et al (2013) Anatomical and clinical characteristics to guide decision making between coronary artery bypass surgery and percutaneous coronary intervention for individual patients: development and validation of SYNTAX score II. Lancet (London, England) 381(9867):639–650. https://doi.org/10.1016/s0140-6736(13)60108-7
doi: 10.1016/s0140-6736(13)60108-7
pubmed: 23439103
(1985) The Thrombolysis in Myocardial Infarction (TIMI) trial. Phase I findings. N Engl J Med 312(14):932–6. https://doi.org/10.1056/nejm198504043121437
Gibson CM, de Lemos JA, Murphy SA et al (2001) Combination therapy with abciximab reduces angiographically evident thrombus in acute myocardial infarction: a TIMI 14 substudy. Circulation 103(21):2550–2554. https://doi.org/10.1161/01.cir.103.21.2550
doi: 10.1161/01.cir.103.21.2550
pubmed: 11382722
Poli A, Fetiveau R, Vandoni P et al (2002) Integrated analysis of myocardial blush and ST-segment elevation recovery after successful primary angioplasty: real-time grading of microvascular reperfusion and prediction of early and late recovery of left ventricular function. Circulation 106(3):313–318. https://doi.org/10.1161/01.cir.0000022691.71708.94
doi: 10.1161/01.cir.0000022691.71708.94
pubmed: 12119246
Baldi C, Polito MV, Citro R et al (2017) Prognostic value of clinical, echocardiographic and angiographic indicators in patients with large anterior ST-segment elevation myocardial infarction as a first acute coronary event. J Cardiovasc Med (Hagerstown) 18(12):946–953. https://doi.org/10.2459/jcm.0000000000000528
doi: 10.2459/jcm.0000000000000528
pubmed: 28604505
Mehran R, Rao SV, Bhatt DL et al (2011) Standardized bleeding definitions for cardiovascular clinical trials: a consensus report from the Bleeding Academic Research Consortium. Circulation 123(23):2736–2747. https://doi.org/10.1161/circulationaha.110.009449
doi: 10.1161/circulationaha.110.009449
pubmed: 21670242
Glynn RJ, Schneeweiss S, Stürmer T (2006) Indications for propensity scores and review of their use in pharmacoepidemiology. Basic Clin Pharmacol Toxicol 98(3):253–259. https://doi.org/10.1111/j.1742-7843.2006.pto_293.x
doi: 10.1111/j.1742-7843.2006.pto_293.x
pubmed: 16611199
pmcid: 1790968
Patrick AR, Schneeweiss S, Brookhart MA et al (2011) The implications of propensity score variable selection strategies in pharmacoepidemiology: an empirical illustration. Pharmacoepidemiol Drug Saf 20(6):551–559. https://doi.org/10.1002/pds.2098
doi: 10.1002/pds.2098
pubmed: 21394812
pmcid: 3123427
Sterne JA, White IR, Carlin JB et al (2009) Multiple imputation for missing data in epidemiological and clinical research: potential and pitfalls. BMJ 338:b2393. https://doi.org/10.1136/bmj.b2393
doi: 10.1136/bmj.b2393
pubmed: 19564179
pmcid: 2714692
Grimfjärd P, Lagerqvist B, Erlinge D, Varenhorst C, James S (2019) Clinical use of cangrelor: nationwide experience from the Swedish Coronary Angiography and Angioplasty Registry (SCAAR). Eur Heart J Cardiovasc Pharmacother 5(3):151–157. https://doi.org/10.1093/ehjcvp/pvz002
doi: 10.1093/ehjcvp/pvz002
pubmed: 30698669
Franchi F, Rollini F, Rivas A et al (2019) Platelet inhibition with cangrelor and crushed ticagrelor in patients with ST-segment-elevation myocardial infarction undergoing primary percutaneous coronary intervention. Circulation 139(14):1661–1670. https://doi.org/10.1161/circulationaha.118.038317
doi: 10.1161/circulationaha.118.038317
pubmed: 30630341
Franchi F, Ortega-Paz L, Rollini F et al (2023) Cangrelor in patients with coronary artery disease pretreated with ticagrelor: the switching antiplatelet (SWAP)-5 study. JACC Cardiovasc Interv 16(1):36–46. https://doi.org/10.1016/j.jcin.2022.10.034
doi: 10.1016/j.jcin.2022.10.034
pubmed: 36317958
Zeymer U, Lober C, Richter S et al (2023) Cangrelor in patients with percutaneous coronary intervention for acute myocardial infarction after cardiac arrest and/or with cardiogenic shock. Eur Heart J Acute Cardiovasc Care 12(7):462–463. https://doi.org/10.1093/ehjacc/zuad041
doi: 10.1093/ehjacc/zuad041
pubmed: 37042356
Kordis P, Bozic Mijovski M, Berden J, Steblovnik K, Blinc A, Noc M (2023) Cangrelor for comatose survivors of out-of-hospital cardiac arrest undergoing percutaneous coronary intervention: the CANGRELOR-OHCA study. EuroIntervention 18(15):1269–1271. https://doi.org/10.4244/EIJ-D-22-00675
doi: 10.4244/EIJ-D-22-00675
pubmed: 36484623
pmcid: 10015287
Baldi C, Silverio A, Esposito L et al (2021) Clinical outcome of patients with ST-elevation myocardial infarction and angiographic evidence of coronary artery ectasia. Catheter Cardiovasc Interv 99(2):340–347. https://doi.org/10.1002/ccd.29738
De Luca G, Silverio A, Verdoia M et al (2022) Angiographic and clinical outcome of SARS-CoV-2 positive patients with ST-segment elevation myocardial infarction undergoing primary angioplasty: a collaborative, individual patient data meta-analysis of six registry-based studies. Eur J Intern Med 105:69–76. https://doi.org/10.1016/j.ejim.2022.08.021
doi: 10.1016/j.ejim.2022.08.021
pubmed: 35999094
pmcid: 9385833
Gargiulo G, Esposito G, Avvedimento M et al (2020) Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS-FASTER trial. Circulation 142(5):441–454. https://doi.org/10.1161/circulationaha.120.046928
doi: 10.1161/circulationaha.120.046928
pubmed: 32795098
pmcid: 7392586
Angiolillo DJ, Bhatt DL, Stone GW (2021) Letter by Angiolillo et al regarding article, “Cangrelor, tirofiban, and chewed or standard prasugrel regimens in patients with ST-segment-elevation myocardial infarction: primary results of the FABOLUS FASTER trial.” Circulation 143(13):e795–e796. https://doi.org/10.1161/circulationaha.120.050205
doi: 10.1161/circulationaha.120.050205
pubmed: 33779271
Vaduganathan M, Harrington RA, Stone GW et al (2017) Evaluation of ischemic and bleeding risks associated with 2 parenteral antiplatelet strategies comparing cangrelor with glycoprotein IIb/IIIa inhibitors: an exploratory analysis from the CHAMPION Trials. JAMA Cardiol 2(2):127–135. https://doi.org/10.1001/jamacardio.2016.4556
doi: 10.1001/jamacardio.2016.4556
pubmed: 27902833
Yerasi C, Case BC, Chezar-Azerrad C et al (2021) Cangrelor vs. glycoprotein IIb/IIIa inhibitors during percutaneous coronary intervention. Am Heart J 238:59–65. https://doi.org/10.1016/j.ahj.2021.04.013
Silverio A, Buccheri S, Venetsanos D et al (2020) Percutaneous treatment and outcomes of small coronary vessels: a SCAAR report. JACC Cardiovasc Interv 13(7):793–804. https://doi.org/10.1016/j.jcin.2019.10.062
doi: 10.1016/j.jcin.2019.10.062
pubmed: 32061601